Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA Chief People Officer Manuela Valente reported open-market sales of company ordinary shares that were made to cover tax obligations from recent restricted stock unit vesting. The transactions, totaling 4,973 shares sold at prices around $4.85 per share, were executed under a pre-established Rule 10b5-1 trading plan.
Following these sales, Valente continues to hold 219,275 ordinary shares directly. Because the trades were specifically to satisfy tax withholding and were pre-planned, they reflect routine administration of equity compensation rather than discretionary buying or selling decisions.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported open-market sales of ordinary shares tied to tax withholding on recently vested restricted stock units. The transactions covered a total of 5,100 shares at weighted average prices around $4.86 per share.
According to the disclosure, the sales were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary trades to satisfy tax obligations. Following these transactions, Xu directly holds 644,952 ordinary shares.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported open-market sales of a total of 3,549 Ordinary Shares to cover tax obligations from recently vested restricted stock units. The sales on April 6 and 7, 2026 were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary.
After these transactions, Verma directly holds 204,400 Ordinary Shares.
SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported equity awards consisting of new options and restricted stock units tied to ordinary shares. The filing shows a grant of share options to purchase 142,216 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. A separate award granted 97,536 ordinary shares in the form of restricted stock units, with 25% of both the RSUs and options vesting on April 2, 2027 and the remainder vesting in installments through April 2, 2030. After these awards, Van Well is shown as beneficially owning 358,774 ordinary shares. This Form 4/A amends a prior report to correct the post-transaction ordinary share balance, which had been understated.
SOPHiA GENETICS SA President Ross Muken received new equity awards and corrected his reported share holdings. On April 2, 2026 he was granted options to buy 628,743 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036.
He also received 431,211 restricted stock units, each representing one ordinary share, bringing his directly held ordinary shares to 703,121 after the grant. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, contingent on continued service.
The share options vest 25% on April 2, 2027 and then in equal monthly installments through April 2, 2030. This amended filing corrects a prior report that had understated his post-transaction ordinary share holdings.
CARDOZA GEORGE reported acquisition or exercise transactions in this Form 4 filing.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza received new equity awards and corrected a prior ownership figure. On April 2, 2026 he was granted options to buy 164,671 ordinary shares at $5.04 per share, vesting 25% on April 2, 2027 and then monthly through April 2, 2030. He also received 112,936 restricted stock units, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030. After these awards, he beneficially owns 297,794 ordinary shares directly, correcting a previously reported amount of 112,936 shares that was described as an inadvertent error.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported awards of share-based incentives and corrected his reported holdings. He received a share option for 628,743 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036.
He was also granted 431,211 restricted stock units, each representing one ordinary share, under the 2021 Equity Incentive Plan. Following these grants, his beneficially owned ordinary shares are correctly reported as 3,734,050, revising a previously misstated amount in an earlier Form 4.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported equity compensation grants consisting of options and restricted stock units tied to ordinary shares. He received a share option covering 164,671 ordinary shares at an exercise price of $5.04 per share, vesting 25% on April 2, 2027 and monthly through April 2, 2030. He also received 112,936 RSUs, each representing one ordinary share, vesting 25% on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030, subject to continued service. Following these grants, his beneficial ownership of ordinary shares was corrected to 286,552 shares due to an earlier inadvertent reporting error.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity compensation awards and corrected prior ownership data. He received a grant of 82,335 share options with a $5.04 exercise price expiring on April 2, 2036, plus 56,468 RSUs. The Form 4/A updates his beneficial ownership to 148,854 ordinary shares after these awards, amending an earlier filing that understated this amount.
SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards and corrected her reported share holdings. She was granted an option for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. Following these awards and a correction to a prior report, her directly held ordinary shares are reported as 224,248.